Atossa Genetics (NASDAQ:ATOS) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Atossa Genetics (NASDAQ:ATOS) from a strong sell rating to a sell rating in a research report sent to investors on Saturday.

ATOS has been the subject of several other research reports. Rodman & Renshaw initiated coverage on shares of Atossa Genetics in a research note on Tuesday, July 7th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings lowered shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $20.33.

Atossa Genetics Trading Up 1.6%

Shares of Atossa Genetics stock opened at $2.60 on Friday. The stock has a fifty day simple moving average of $2.39 and a 200 day simple moving average of $4.26. Atossa Genetics has a 12-month low of $1.70 and a 12-month high of $19.35. The company has a market capitalization of $25.95 million, a P/E ratio of -0.84 and a beta of 1.29.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.07. On average, analysts predict that Atossa Genetics will post -4.3 EPS for the current year.

Institutional Trading of Atossa Genetics

A number of hedge funds have recently bought and sold shares of ATOS. &PARTNERS purchased a new position in Atossa Genetics in the fourth quarter worth $25,000. Hudson Bay Capital Management LP purchased a new stake in shares of Atossa Genetics during the 2nd quarter valued at $26,000. JPMorgan Chase & Co. increased its position in shares of Atossa Genetics by 1,294.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares during the last quarter. Bank of America Corp DE increased its position in shares of Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after purchasing an additional 35,629 shares during the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Atossa Genetics by 581.2% during the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after purchasing an additional 144,412 shares during the period. 12.74% of the stock is currently owned by institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.